This paper reviews the mechanisms of anaphylactic shock in terms of the immunoglobulin and non-immunoglobulin triggering events, and the cellular events based on the rise in intracellular cyclic AMP and calcium that release preformed granule-associated mediators and the rapidly formed, newly synthesized mediators predominantly based on arachidonic acid metabolism. These primary mediators recruit other cells with the release of secondary mediators that either potentiate or ultimately curtail the anaphylactic reaction. The roles of these mediators in the various causes of cardiovascular collapse are examined. The treatment of anaphylactic shock involves oxygen, adrenaline and fluids. The importance and safety of intravenous adrenaline are discussed.
DEFINITION
Currently, the term anaphylaxis is best used to describe the rapid, generalized and often unanticipated, immunologically mediated events that occur after exposure to certain foreign substances in previously sensitized persons. Anaphylactoid reactions describe a clinically identical syndrome involving similar mediators but not triggered by IgE antibody and not necessarily requiring previous exposure. Despite important aetiological distinctions, the term anaphylaxis is commonly used to describe both of these clinical syndromes, even when the mechanisms are unknown. 3 The most common life-threatening feature of acute anaphylaxis is cardiovascular collapse or shock. Other life-threatening effects include bronchospasm, angio-oedema and pulmonary oedema.6'7 This paper will focus on the mechanisms and both general and specific treatment of anaphylactic shock.
into four main categories: the events that trigger the anaphylactic reaction; the cellular events that then lead to mediator release; the clinical pharmacology of these mediators; and finally the cardiovascular responses of patients to these mediators.
MECHANISMS: TRIGGERING EVENTS
The events that trigger anaphylaxis are either anaphylactic and IgE immunologically mediated, or anaphylactoid and non-immunoglobulin mediated, although in many reactions there is evidence of the involvement of multiple pathways (see Table 1 ). Table 3 ). the lipoxygenase pathway to form leukotrienes. These rapidly formed, newly synthesized primary mediators include the following: prostaglandin D2; thromboxane A2; leukotrienes such as B4 (LTB4) and C, D and E4 (LTC4, LTD4 and LTE4) previously called slow-reacting substance of anaphylaxis; plateletactivating factor (PAF); cytokines such as tumour necrosis factor and interleukins; adenosine and free oxygen radicals15'24 (see Table 4 ).
ANAPHYLACTIC IgE ANTIBODY REACTIONS
At a cellular level, mediator release may be modulated by the steady-state, resting intracellular cyclic AMP levels. The importance of this is that substances that elevate cyclic AMP, such as adrenaline, inhibit mediator release, whereas substances that decrease cyclic AMP or increase reciprocal changes in cyclic GMP, such as cholinergic agents, augment mediator release.511 access secured to support the circulation. The mechanisms and mainstay of treatment for anaphylactic shock is treatment oxygen, adrenaline and fluids.' 3 22 (see Table 7 ). Fisher's leader in the British Medical Journal in 1992 discussed the issues concerning the relevance and safety of intravenous adrenaline in anaphylaxis.6 He noted that no one route of administration is likely to be right in all cases, and that the timing of administration of the drug may be critical. He suggested that, as vasodilatation is the main pathological change early in anaphylaxis, this enables the subcutaneous or intramuscular absorption of adrenaline to be rapid and effective. Thus, when the disease is treated early and is progressing slowly, or venous access is difficult or the patient is unmonitored, intramuscular adrenaline has advantages in terms of safety and is usually effective. Later, when intravascular volume is depleted and shock occurs, or there is severe dyspnoea or airway compromise, the intravenous route is necessary to achieve optimal absorption. In addition, Fisher considered that, in most cases, the recommended published intramuscular or subcutaneous doses were too high.
ROLE OF ADRENALINE
He advised doses of 0.3-0.5mg of 1 in 1000 adrenaline administered subcutaneously or intramuscularly, and he recommended that the standard intravenous dose should be up to 3 mL of 1 in 10 000 adrenaline administered slowly. Fisher concluded with the diplomatic assertion that 'in severe anaphylaxis adrenaline by any route is better than none'. 6 The Association of Anaesthetists of Great Britain and Ireland published a monograph in 1990 that further supports the importance and safety of intravenous adrenaline in anaphylaxis.56 They recommended using adrenaline under ECG monitoring in an initial dose of 50-100pg, particularly for hypotension or bronchospasm, followed by an infusion if prolonged therapy is required.
ADRENALINE: INTRAVENOUS DILUTION
Finally, there is disagreement over the correct dilution for the administration of intravenous adrenaline. Whilst the 1 in 10000 dilution is favoured by some, a further tenfold dilution to 1 in 100 000 is suggested by many authors in order to minimize adverse reactions.2944-4657 Thus Barach and Nowak recommend using 1 mL of 1 in 10 000 adrenaline diluted to 10mL, giving a final concentration of 10pgmL ' , administered under A.FT 7 Brown ECG monitoring at the rate of 10 pg or 1 mL min-' 4-This may be followed by an infusion from [1] [2] [3] [4] 
CONCLUSIONS
The three most common causes of anaphylactic fatalities are parenteral penicillin administration (100-500 deaths per year in the USA), Hymenoptera stings (40-100 deaths per year in the USA) and food-related reactions.89 Radio-contrast media reactions (up to 500 deaths per year in the USA)90 and aspirin or other non-steroidal antiinflammatory drugs are the two most common causes of anaphylactoid fatalities. 91 The diagnosis of anaphylaxis is not difficult when a patient presents with generalized urticaria, wheeze-and circulatory collapse following a bee sting. However, circulatory collapse may occur rapidly in anaphylaxis without preceding skin or respiratory manifestations. There is no immediately available laboratory test to confirm the diagnosis of anaphylaxis. Serum tryptase levels are an accurate marker of mast cell degranulation that may be measured up to 6 h after the event by radioimmunoassay, but they are restricted to specialized immunology laboratories.92 Thus, the purely clinical recognition and prompt treatment of anaphylaxis represents one of the ultimate challenges to emergency physicians in their daily practice.
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